OncoMatch/Clinical Trials/NCT04447352
HIPEC + FLOT vs. FLOT Alone in Patients With Gastric Cancer and GEJ (PREVENT)
Is NCT04447352 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments for gastric cancer.
Treatment: 5-Fluorouracil · Leucovorin · Oxaliplatin · Docetaxel · Cisplatin — This is a multicenter, randomized, controlled, open-label study evaluating efficacy and safety of perioperative FLOT chemotherapy plus intraoperative HIPEC versus FLOT chemotherapy alone in patients with resectable localized and locally advanced diffuse and mixed type adenocarcinoma of the stomach and Type II/III GEJ.
Check if I qualifyExtracted eligibility criteria
Cancer type
Gastric Cancer
Esophageal Carcinoma
Disease stage
Required: Stage UT3, UT4A, ANY T N+ M0
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: FLOT chemotherapy (5-FU, leucovorin, oxaliplatin, docetaxel) — neoadjuvant
Patient has received 3 to 6 cycles of neoadjuvant FLOT (de-escalation or dose modification allowed)
Cannot have received: cytotoxic or targeted therapy
Exception: other than neoadjuvant FLOT (including de-escalated or dose reduced schema) therapy
No preceding cytotoxic or targeted therapy other than neoadjuvant FLOT (including de-escalated or dose reduced schema) therapy
Cannot have received: tumor resection
No prior partial or complete tumor resection
Lab requirements
Blood counts
adequate to allow surgical procedure and hipec at investigator´s discretion
Kidney function
adequate to allow surgical procedure and hipec at investigator´s discretion
Liver function
adequate to allow surgical procedure and hipec at investigator´s discretion
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify